Literature DB >> 19326986

Effect of trans sodium crocetinate on brain tumor oxygenation. Laboratory investigation.

Jason Sheehan1, Jonathan Sherman, Christopher Cifarelli, Jay Jagannathan, Kasandra Dassoulas, Claire Olson, Jessica Rainey, Shaojie Han.   

Abstract

OBJECT: Glioblastoma multiforme tumors typically exhibit regions of hypoxia. Hypoxic regions within the tumor make cells less sensitive to radiosurgery and radiation therapy. Trans sodium crocetinate (TSC) has been shown to be a radiosensitizer. The goal of this research was to elucidate the underlying mechanism of TSC's radiosensitizing effect.
METHODS: A rat C6 glioma model was used. The C6 glioma cells were stereotactically injected into the rat brain to create a tumor. Two weeks later, MR imaging was used to confirm the presence of a glioma. Following demonstration on MR imaging of a brain tumor, animals were randomized into 1 of 2 groups: 1) TSC alone (100 microg/kg), or 2) saline control. Licox probes were inserted into the brain tumor and contralateral cerebral hemisphere. Tissue oxygenation measurements were recorded before and after intravenous infusion of either TSC or saline.
RESULTS: Not surprisingly, tissue oxygenation measurements revealed that the brain tumor was hypoxic relative to the contralateral cerebral hemisphere brain tissue. Two to 8 minutes after TSC was infused, tissue oxygenation measurements in the brain tumor increased above baseline by as much as 60%. After this temporary elevation following TSC infusion, tumor oxygenation measurements returned to baseline. No significant elevations in tissue oxygenation were seen on the contralateral side. Similarly, the saline vehicle was not observed to increase tissue oxygenation in either the brain tumor or the contralateral brain tissue.
CONCLUSIONS: Administration of TSC transiently improves tissue oxygenation in hypoxic gliomas. Such an effect is one potential mechanism for the radiosensitization previously observed after addition of TSC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326986     DOI: 10.3171/2009.3.JNS081339

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke.

Authors:  Yi Wang; Ryo Yoshimura; Hiroaki Manabe; Catherine Schretter; Ryon Clarke; Yu Cai; Mark Fitzgerald; Kevin S Lee
Journal:  Brain Res       Date:  2014-08-14       Impact factor: 3.252

Review 2.  Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia.

Authors:  Devarajan Nalini; Jayaraman Selvaraj; Ganesan Senthil Kumar
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-13       Impact factor: 4.553

3.  Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.

Authors:  Jennifer L H Johnson; Rafael A Leos; Amanda F Baker; Evan C Unger
Journal:  J Biomed Nanotechnol       Date:  2015-02       Impact factor: 4.099

Review 4.  Emerging Applications of Ultrasound-Contrast Agents in Radiation Therapy.

Authors:  Quezia Lacerda; Mohamed Tantawi; Dennis B Leeper; Margaret A Wheatley; John R Eisenbrey
Journal:  Ultrasound Med Biol       Date:  2021-02-27       Impact factor: 3.694

Review 5.  Saffron: An Old Medicinal Plant and a Potential Novel Functional Food.

Authors:  María José Bagur; Gonzalo Luis Alonso Salinas; Antonia M Jiménez-Monreal; Soukaina Chaouqi; Silvia Llorens; Magdalena Martínez-Tomé; Gonzalo L Alonso
Journal:  Molecules       Date:  2017-12-23       Impact factor: 4.411

Review 6.  Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.

Authors:  Kaitlin Graham; Evan Unger
Journal:  Int J Nanomedicine       Date:  2018-10-04

Review 7.  Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma.

Authors:  Yandong Xie; Yuhan Han; Xuefeng Zhang; Hongwei Ma; Linfeng Li; Rutong Yu; Hongmei Liu
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.